Homology Medicines. has filed a patent for recombinant adeno-associated virus (AAV) capsid proteins, compositions, nucleic acids, and methods of making and using the capsid proteins. Claim 1 has been canceled. GlobalData’s report on Homology Medicines gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Homology Medicines, Adeno-associated virus vectors was a key innovation area identified from patents. Homology Medicines's grant share as of January 2024 was 4%. Grant share is based on the ratio of number of grants to total number of patents.
Recombinant aav capsid proteins for gene therapy
The patent application (Publication Number: US20230399657A1) discloses a novel recombinant adeno-associated virus (AAV) capsid protein with specific amino acid sequences, distinct from the wild type, for potential therapeutic applications. The recombinant AAV capsid protein described in the claims features specific amino acid substitutions at positions 346, 501, 505, and 706 of the protein sequence, offering unique properties compared to the wild type capsid protein. Additionally, the patent covers variants of the recombinant AAV capsid protein belonging to various clades and with high sequence similarity to specific amino acid sequences.
Furthermore, the patent application encompasses methods for producing the recombinant AAV capsid protein, vectors containing the polynucleotide encoding the protein, recombinant cells expressing the protein, and recombinant AAVs incorporating the novel capsid protein for gene delivery and editing purposes. The disclosed methods include culturing recombinant cells under specific conditions to express the capsid protein, transducing cells with the recombinant AAV for gene delivery, and editing target loci in cell genomes using the recombinant AAV. Additionally, the patent application describes a packaging system comprising nucleotide sequences encoding AAV Rep proteins, the recombinant AAV capsid protein, and an rAAV genome sequence for the preparation of recombinant AAVs. Overall, the patent application presents a comprehensive framework for utilizing the novel recombinant AAV capsid protein in various biotechnological and therapeutic applications.
To know more about GlobalData’s detailed insights on Homology Medicines, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
